Working… Menu
Trial record 1 of 1 for:    Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab
Previous Study | Return to List | Next Study

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03747120
Recruitment Status : Recruiting
First Posted : November 20, 2018
Last Update Posted : January 15, 2021
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Heather McArthur, Cedars-Sinai Medical Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2023